Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Scynexis Q3 2026 Results: Net Loss of $8.46M, Loss Narrows

SCYNEXIS reported a net loss of $8.5 million for Q3 2026, with research and development expenses increasing to $6.2 million as the company advances its SCY-770 and SCY-247 programs. The company's liquidity was significantly bolstered by a $40.0 million private placement in March 2026 and a new BARDA contract awarded in September 2026 providing up to $213.9 million in potential non-dilutive funding.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.3
Net income-8.5-8.6
EPS (diluted, $ a share)$-0.71$-1.38

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: SCYX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Scynexis Inc: key numbers

Share price
$2.91Close, Nov 16
Market cap
$29M
Shares outstanding
9.95MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Scynexis Inc

All →
4:02 PM ET 8-K
Contract Win

Scynexis Wins $214M Contract from Biomedical Advanced Research and Development Authority

SCYNEXIS was awarded a contract from BARDA providing up to $214 million in non-dilutive funding to support the development of SCY-247, a second-generation antifungal candidate. The agreement includes an initial $18.5 million base period to advance the candidate into Phase 2 studies for invasive candidiasis, with subsequent options that could fund the program through NDA submission.

Value
$214M
Counterparty
Biomedical Advanced Research and Development Authority (BARDA)
Term
up to 10 years

“We are proud to partner with BARDA to advance the development of SCY-247, our antifungal designed to address the growing threat of antimicrobial resistance.”

David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS

“While we remain focused on SCY-770, our new product candidate for ADPKD, this partnership enables the development of a novel therapy for the treatment and prevention of serious invasive fungal infections while leveraging our existing infrastructure and capabilities.”

David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS
8:06 AM ET 8-K
Executive Compensation

Scynexis Executive Compensation

SCYNEXIS appointed Steven K. Burke, M.D., to its Board of Directors and the Nominating and Corporate Governance Committee. Dr. Burke will receive an annual cash retainer of $45,000 plus $5,000 for committee service, along with initial equity grants of 5,750 stock options and 5,750 restricted stock units. The appointment adds deep nephrology drug development expertise as the company prepares to advance its ADPKD candidate, SCY-770, into Phase 2 trials.

Counterparty
Steven K. Burke, M.D.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.